Catridecacog
NovoThirteen (catridecacog) is a protein pharmaceutical. Catridecacog was first approved as NovoThirteen on 2012-09-03. It has been approved in Europe to treat inherited blood coagulation disorders.
Trade Name | NovoThirteen |
---|---|
Common Name | Catridecacog |
Indication | inherited blood coagulation disorders |
Drug Class |
